Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday.
TCMD has been the subject of several other research reports. B. Riley started coverage on Tactile Systems Technology in a report on Thursday, September 26th. They issued a “buy” rating and a $23.00 price target for the company. Oppenheimer cut Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, BTIG Research lowered shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th.
Read Our Latest Analysis on TCMD
Tactile Systems Technology Stock Performance
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in TCMD. Arcadia Investment Management Corp MI acquired a new stake in shares of Tactile Systems Technology in the 3rd quarter valued at $29,000. Gladius Capital Management LP acquired a new stake in Tactile Systems Technology in the third quarter worth about $44,000. Quarry LP bought a new stake in Tactile Systems Technology during the 2nd quarter worth about $46,000. Magnetar Financial LLC acquired a new position in Tactile Systems Technology during the 2nd quarter valued at about $130,000. Finally, SG Americas Securities LLC bought a new position in shares of Tactile Systems Technology in the 3rd quarter valued at about $156,000. 83.43% of the stock is owned by institutional investors.
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
See Also
- Five stocks we like better than Tactile Systems Technology
- Industrial Products Stocks Investing
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- How to Calculate Inflation Rate
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Why Are These Companies Considered Blue Chips?
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.